Drug Profile

Palbociclib - Onyx Pharmaceuticals/Pfizer

Alternative Names: Bapocil; IBRANCE; Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 17 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onyx Pharmaceuticals; Pfizer; SOLTI Breast Cancer Research Group
Developer Assistance Publique Hopitaux de Paris; Bergonie Institute; Calithera Biosciences; Canadian Cancer Trials Group; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; European Organisation for Research and Treatment of Cancer; Georgetown University; German Breast Group; Grupo Espanol de Tumores Neuroendocrinos; GSK; International Breast Cancer Study Group; iOMEDICO AG; Karolinska Institute; National Cancer Institute (USA); Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; UNICANCER; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Breast cancer
Phase III HER2 negative breast cancer
Phase II/III Non-small cell lung cancer
Phase II Adenocarcinoma; Bone metastases; Brain metastases; Gastrointestinal stromal tumours; Mantle-cell lymphoma; Pancreatic cancer; Prostate cancer; Squamous cell cancer; Urogenital cancer
Phase I/II Colorectal cancer; Malignant melanoma
No development reported Acute myeloid leukaemia; Glioblastoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
Discontinued Astrocytoma; Glioma

06 Jul 2026 Efficacy data from a phase III PATINA trial in Breast cancer released by Dana-Farber Cancer Institute
01 Jul 2026 Launched for Breast cancer (Metastatic disease, Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA (PO)
24 Jun 2026 Registered for Breast cancer (Metastatic disease, Inoperable/Unresectable, Combination therapy, Late-stage disease) in USA (PO)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com